The Effect of Proton Pump Inhibitors on Glycemic Control in Patients with Type 2 Diabetes

Kelly Villegas, Joy L. Meier, Maureen Long, Julio Lopez, Arthur L Swislocki

Research output: Contribution to journalArticle

Abstract

Background: Type 2 diabetes patients have decreased pancreatic beta cell mass with a decline in beta cell function. Gastrin has increased beta cell proliferation in vitro and in animal studies. High gastric acid levels inhibit gastrin secretion. Proton pump inhibitors (PPIs) lower gastric acid, subsequently increasing gastrin levels. This may stimulate beta cell proliferation and function, and improve glycemic control. Studies with small numbers of type 2 diabetes patients have shown a slightly lower A1C in those taking PPI versus non-PPI users. Methods: This study was a retrospective multicenter electronic data analysis using data obtained from health care facilities within Veterans Integrated Service Network (VISN) 21. Patients were included if they had established care within VISN 21 and had type 2 diabetes with an A1C > 6.5%, were started on a PPI concurrently with stable doses of metformin or sulfonylurea (SFU) monotherapy, had at least two documented A1C values, and had a medication possession ratio >80% for metformin, SFU, or a PPI. Veterans were excluded if they were using insulin, combination antihyperglycemic therapy, or oral corticosteroids. A control group not using PPI was also identified. Results: There was a statistically significant decrease in A1C within each group. However, there was no statistically significant difference between the PPI and control group in the post-A1C. Conclusion: In patients with type 2 diabetes, A1C improved in both groups, but PPI addition did not affect glycemic control. Future randomized controlled trials are needed to determine the value of PPIs as a treatment option for patients with type 2 diabetes.

Original languageEnglish (US)
Pages (from-to)192-196
Number of pages5
JournalMetabolic Syndrome and Related Disorders
Volume17
Issue number4
DOIs
StatePublished - May 1 2019

Fingerprint

Proton Pump Inhibitors
Type 2 Diabetes Mellitus
Gastrins
Veterans
Metformin
Gastric Acid
Cell Proliferation
Control Groups
Health Facilities
Insulin-Secreting Cells
Hypoglycemic Agents
Adrenal Cortex Hormones
Randomized Controlled Trials
Insulin
Delivery of Health Care
Therapeutics

Keywords

  • diabetes
  • glycemic control
  • proton pump inhibitors

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The Effect of Proton Pump Inhibitors on Glycemic Control in Patients with Type 2 Diabetes. / Villegas, Kelly; Meier, Joy L.; Long, Maureen; Lopez, Julio; Swislocki, Arthur L.

In: Metabolic Syndrome and Related Disorders, Vol. 17, No. 4, 01.05.2019, p. 192-196.

Research output: Contribution to journalArticle

Villegas, Kelly ; Meier, Joy L. ; Long, Maureen ; Lopez, Julio ; Swislocki, Arthur L. / The Effect of Proton Pump Inhibitors on Glycemic Control in Patients with Type 2 Diabetes. In: Metabolic Syndrome and Related Disorders. 2019 ; Vol. 17, No. 4. pp. 192-196.
@article{c49530fbe0914792b1e128c269f5408a,
title = "The Effect of Proton Pump Inhibitors on Glycemic Control in Patients with Type 2 Diabetes",
abstract = "Background: Type 2 diabetes patients have decreased pancreatic beta cell mass with a decline in beta cell function. Gastrin has increased beta cell proliferation in vitro and in animal studies. High gastric acid levels inhibit gastrin secretion. Proton pump inhibitors (PPIs) lower gastric acid, subsequently increasing gastrin levels. This may stimulate beta cell proliferation and function, and improve glycemic control. Studies with small numbers of type 2 diabetes patients have shown a slightly lower A1C in those taking PPI versus non-PPI users. Methods: This study was a retrospective multicenter electronic data analysis using data obtained from health care facilities within Veterans Integrated Service Network (VISN) 21. Patients were included if they had established care within VISN 21 and had type 2 diabetes with an A1C > 6.5{\%}, were started on a PPI concurrently with stable doses of metformin or sulfonylurea (SFU) monotherapy, had at least two documented A1C values, and had a medication possession ratio >80{\%} for metformin, SFU, or a PPI. Veterans were excluded if they were using insulin, combination antihyperglycemic therapy, or oral corticosteroids. A control group not using PPI was also identified. Results: There was a statistically significant decrease in A1C within each group. However, there was no statistically significant difference between the PPI and control group in the post-A1C. Conclusion: In patients with type 2 diabetes, A1C improved in both groups, but PPI addition did not affect glycemic control. Future randomized controlled trials are needed to determine the value of PPIs as a treatment option for patients with type 2 diabetes.",
keywords = "diabetes, glycemic control, proton pump inhibitors",
author = "Kelly Villegas and Meier, {Joy L.} and Maureen Long and Julio Lopez and Swislocki, {Arthur L}",
year = "2019",
month = "5",
day = "1",
doi = "10.1089/met.2018.0138",
language = "English (US)",
volume = "17",
pages = "192--196",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - The Effect of Proton Pump Inhibitors on Glycemic Control in Patients with Type 2 Diabetes

AU - Villegas, Kelly

AU - Meier, Joy L.

AU - Long, Maureen

AU - Lopez, Julio

AU - Swislocki, Arthur L

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background: Type 2 diabetes patients have decreased pancreatic beta cell mass with a decline in beta cell function. Gastrin has increased beta cell proliferation in vitro and in animal studies. High gastric acid levels inhibit gastrin secretion. Proton pump inhibitors (PPIs) lower gastric acid, subsequently increasing gastrin levels. This may stimulate beta cell proliferation and function, and improve glycemic control. Studies with small numbers of type 2 diabetes patients have shown a slightly lower A1C in those taking PPI versus non-PPI users. Methods: This study was a retrospective multicenter electronic data analysis using data obtained from health care facilities within Veterans Integrated Service Network (VISN) 21. Patients were included if they had established care within VISN 21 and had type 2 diabetes with an A1C > 6.5%, were started on a PPI concurrently with stable doses of metformin or sulfonylurea (SFU) monotherapy, had at least two documented A1C values, and had a medication possession ratio >80% for metformin, SFU, or a PPI. Veterans were excluded if they were using insulin, combination antihyperglycemic therapy, or oral corticosteroids. A control group not using PPI was also identified. Results: There was a statistically significant decrease in A1C within each group. However, there was no statistically significant difference between the PPI and control group in the post-A1C. Conclusion: In patients with type 2 diabetes, A1C improved in both groups, but PPI addition did not affect glycemic control. Future randomized controlled trials are needed to determine the value of PPIs as a treatment option for patients with type 2 diabetes.

AB - Background: Type 2 diabetes patients have decreased pancreatic beta cell mass with a decline in beta cell function. Gastrin has increased beta cell proliferation in vitro and in animal studies. High gastric acid levels inhibit gastrin secretion. Proton pump inhibitors (PPIs) lower gastric acid, subsequently increasing gastrin levels. This may stimulate beta cell proliferation and function, and improve glycemic control. Studies with small numbers of type 2 diabetes patients have shown a slightly lower A1C in those taking PPI versus non-PPI users. Methods: This study was a retrospective multicenter electronic data analysis using data obtained from health care facilities within Veterans Integrated Service Network (VISN) 21. Patients were included if they had established care within VISN 21 and had type 2 diabetes with an A1C > 6.5%, were started on a PPI concurrently with stable doses of metformin or sulfonylurea (SFU) monotherapy, had at least two documented A1C values, and had a medication possession ratio >80% for metformin, SFU, or a PPI. Veterans were excluded if they were using insulin, combination antihyperglycemic therapy, or oral corticosteroids. A control group not using PPI was also identified. Results: There was a statistically significant decrease in A1C within each group. However, there was no statistically significant difference between the PPI and control group in the post-A1C. Conclusion: In patients with type 2 diabetes, A1C improved in both groups, but PPI addition did not affect glycemic control. Future randomized controlled trials are needed to determine the value of PPIs as a treatment option for patients with type 2 diabetes.

KW - diabetes

KW - glycemic control

KW - proton pump inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85065252715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065252715&partnerID=8YFLogxK

U2 - 10.1089/met.2018.0138

DO - 10.1089/met.2018.0138

M3 - Article

C2 - 30730235

AN - SCOPUS:85065252715

VL - 17

SP - 192

EP - 196

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 4

ER -